Document 0896
 DOCN  M95A0896
 TI    Pulmonary infection in the immunocompromised patient.
 DT    9510
 AU    White DA; Department of Medicine, Memorial Sloan-Kettering Cancer
       Center,; New York, NY 10021, USA.
 SO    Semin Thorac Cardiovasc Surg. 1995 Apr;7(2):78-87. Unique Identifier :
       AIDSLINE MED/95337243
 AB    Pneumonia in the immunocompromised patient remains a significant cause
       of morbidity and mortality. These patients are susceptible to a wide
       variety of organisms, but specific infections tend to occur in well
       defined settings. The type of infection can be predicted based on the
       nature and severity of the immune defect, past patient exposures,
       chemotherapy given, radiographic presentation, and acuteness of illness.
       New treatments, including growth factors, the oral antifungal agents,
       and antiviral drugs, such as ganciclovir and acyclovir, have improved
       management and prognosis in some cases. However, some problems have
       increased with a significant risk of spontaneous pneumothorax now seen
       with Pneumocystis carinii infection. Bronchoscopy with bronchoalveolar
       lavage plays a major role in diagnosis, particularly for P carinii and
       cytomegalovirus infection. However, open lung biopsy remains essential
       for diagnosis in some settings. Surgical resection for control of
       hemoptysis and for removal of residual foci of disease also are an
       integral part of management of pulmonary fungal infections in the
       immunosuppressed patient.
 DE    AIDS-Related Opportunistic Infections/*IMMUNOLOGY  Biopsy/METHODS  Human
       *Immunocompromised Host  Lung/PATHOLOGY  Lung Diseases,
       Fungal/*IMMUNOLOGY  Lung Diseases, Parasitic/*IMMUNOLOGY  Pneumonia,
       Bacterial/*IMMUNOLOGY  Pneumonia, Viral/*IMMUNOLOGY  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).